Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484600 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01484600 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT01484600, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers.
Interventions
- DRUG REGN668: Injection Rate 1
- DRUG REGN668: Injection Rate 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01484600
The ClinicalTrials.gov registry entry for NCT01484600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which REGN668: Injection Rate 1 is the first listed.
NCT01484600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01484600 about?
NCT01484600 is a clinical study titled "Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers". This is a study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers.
What is the current status of trial NCT01484600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2011-12. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01484600?
The interventions under investigation include: REGN668: Injection Rate 1 (DRUG), REGN668: Injection Rate 2 (DRUG).
Who is sponsoring clinical trial NCT01484600?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.